Molly Delk Plummer, Fredric Regenstein – 26 August 2021 – Light chain deposition disease (LCDD) is a rare entity that is generally discovered in the setting of solid organ dysfunction. The monoclonal gammopathy leads to abnormal deposition of light chains in tissues, most often manifested by way of renal dysfunction. Other organ systems may also be affected, the liver being the second‐most common after the kidneys. Liver involvement rarely leads to clinically significant disease, with few case reports in the literature.

Abdul Rahman Hakeem, Ashwin Rammohan, Mukul Vij, Mohamed Rela – 26 August 2021

Laurens A. Kleef, Ibrahim Ayada, Louise J.M. Alferink, Qiuwei Pan, Robert J. Knegt – 26 August 2021

Adriana Psaraki, Lydia Ntari, Christos Karakostas, Despoina Korrou‐Karava, Maria G. Roubelakis – 26 August 2021 – Liver dysfunctions are classified into acute and chronic diseases, which comprise a heterogeneous group of pathological features and a high mortality rate. Liver transplantation remains the gold‐standard therapy for most liver diseases, with concomitant limitations related to donor organ shortage and lifelong immunosuppressive therapy.

José María Remes‐Troche, José Antonio Velarde‐Ruiz Velasco – 26 August 2021

José María Remes‐Troche, José Antonio Velarde‐Ruiz Velasco – 26 August 2021

Gina M. Gallucci, Jocelyn Trottier, Christopher Hemme, David N. Assis, James L. Boyer, Olivier Barbier, Nisanne S. Ghonem – 26 August 2021 – Accumulation of cytotoxic bile acids (BAs) during cholestasis can result in liver failure. Glucuronidation, a phase II metabolism pathway responsible for BA detoxification, is regulated by peroxisome proliferator–activated receptor alpha (PPARα). This study investigates the efficacy of adjunct fenofibrate therapy to up‐regulate BA‐glucuronidation and reduce serum BA toxicity during cholestasis.

José María Remes‐Troche, José Antonio Velarde‐Ruiz Velasco – 26 August 2021

25 August 2021

25 August 2021